The US FDA has agreed to resume clinical trials with anti-nerve growth (NGF) drugs despite cases of side effects stating the risk-benefit profile indicated a role for their ongoing development. The drugs are being developed for the treatment of a variety of chronic painful conditions, including diabetic peripheral neuropathy. READ MORE
Source: Medscape